Copper Complex Halts Botulinum Neurotoxin Poisoning
|
By HospiMedica International staff writers Posted on 12 Jun 2017 |
A new study describes how a readily available metal salt could provide a new therapy for Botulinum Neurotoxin type A (BoNT/A), the most common and deadly cause of human botulism.
Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.
They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.
“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”
BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.
Related Links:
Scripps Research Institute
Boston University
Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.
They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.
“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”
BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.
Related Links:
Scripps Research Institute
Boston University
Latest Critical Care News
- AI Model Predicts 10-Year Stroke Risk from Standard ECG
- AI Tool Predicts Risk of Out-of-Hospital Cardiac Arrest
- Implantable Cytokine Device Enables Localized Immunotherapy for Ovarian Cancer
- Wearable Defibrillator Supports Quicker Beta-Blocker Optimization in Women
- High-Frequency Ultrasound Disables Viruses While Sparing Human Cells
- New Nasal Spray Enables Prehospital Neuroprotection in Ischemic Stroke
- AI-Enhanced ECG Screens for Heart Failure Risk in Resource-Limited Settings
- Single-Lead AI ECG Tool Detects Moderate-to-Severe Hyperkalemia Outside Clinic
- Reduced-Intensity Transplant Regimen Expands Donor Access in Sickle Cell Disease
- Battery-Free ECG Patch Enables Continuous Arrhythmia Monitoring
- Spinal Cord Interface Restores Bladder Control in Preclinical Study
- Rapid Clotting Gel Improves Emergency Bleeding Control
- AI Tool Predicts In-Hospital Cardiac Arrest Minutes in Advance
- Magnetic Control System Enables Precise Navigation of Miniature Medical Devices
- Shelf-Stable Synthetic Platelets Could Enable Prehospital Hemorrhage Control
- Noninvasive AI Test Aims to Enable Earlier Pulmonary Hypertension Detection
Channels
Artificial Intelligence
view channel
FDA-Cleared AI System Detects Sepsis Earlier and Reduces Mortality
Sepsis remains one of the deadliest complications for hospitalized patients, in part because its early signs overlap with other conditions. Each hour of delayed recognition measurably decreases survival,... Read moreFacial Image Analysis Tracks Biological Aging, Predicts Cancer Outcomes
Biological aging is the progressive loss of physiological function that may diverge from chronological age. In cancer care, clinicians need simple tools that reflect dynamic changes in patient resilience... Read moreSurgical Techniques
view channel
FDA-Cleared Nerve Stimulator Advances Intraoperative Peripheral Nerve Assessment
The Evala Nerve Stimulator from Epineuron (Mississauga, ON, Canada) is a handheld, intraoperative electrical stimulation system designed to provide surgeons with a rapid and accurate method for nerve identification... Read more
Handheld AI Endomicroscope Enables Real-Time Precancer Detection at Point of Care
Many epithelial cancers are detected late because current diagnostics rely on invasive biopsies and in vivo microscopy with narrow field and shallow depth of field. These constraints can make it difficult... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EHR-Integrated Screening Workflow Detects Cognitive Impairment at Admission
Cognitive impairment involves difficulties with thinking, learning, memory, and decision-making, and is more common in older adults. In U.S. hospitals, more than 40% of admitted older adults have dementia,... Read more
AI System Detects and Quantifies Chronic Subdural Hematoma
Viz.ai (San Francisco, CA, USA) announced a strategic commercialization collaboration with Johnson & Johnson (New Brunswick, NJ, USA) to expand access in the United States to the Viz Subdural solution... Read more
Continuous Monitoring Platform Detects Infection Risk Across Care Transitions
Patients leaving skilled nursing facilities often lose continuous physiologic monitoring, increasing the risk of undetected infection and delayed intervention. Nursing home residents are seven times more... Read more
Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings
Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read morePoint of Care
view channel
Point-of-Care Viscoelastic Testing System Supports Obstetric Bleeding Management
HemoSonics (Durham, NC, USA) announced on May 5, 2026 that the company's Quantra Hemostasis System for Obstetric Procedures won Silver in the 2026 Edison Awards in the Women’s Health and Reproductive Innovations... Read moreBusiness
view channel
Olympus Partnership Aims to Expand Access to Robot-Assisted Endoscopic Therapy
Olympus has signed an exclusive global distribution agreement with EndoRobotics Co., Ltd., under which robot-assisted technologies developed by EndoRobotics will be distributed worldwide as part of the... Read more







